SAN DIEGO, March 2, 2006 /PRNewswire-FirstCall via COMTEX News Network/ —ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences:
- The 5th Annual JMP Securities Research Conference on Wednesday, March 8, 2006, at 8:40 a.m. Pacific Time at The Ritz-Carlton in San Francisco.
- The SG Cowen & Co. 26th Annual Health Care Conference on Thursday, March 9, 2006, at 8:50 a.m. Eastern Time at The Boston Marriott Copley Place in Boston.
Live webcasts of these presentations will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through March 23, 2006.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for CNS disorders. ACADIA currently has four drug programs in clinical development as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease, neuropathic pain, and glaucoma. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.
Contacts: ACADIA Pharmaceuticals Inc. Lisa Barthelemy, Director, Investor Relations Thomas H. Aasen, Vice President and Chief Financial Officer (858) 558-2871